FACCHINETTI, FRANCESCO
FACCHINETTI, FRANCESCO
Dipartimento di Neuroscienze (attivo dal 20/07/2012 al 31/12/2016)
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
2021-01-01 Gozzi, F.; Tiseo, M.; Facchinetti, F.; Gandolfi, S.; Rubino, P.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
2020-01-01 Dall'Olio, F. G.; Abbati, F.; Facchinetti, F.; Massucci, M.; Melotti, B.; Squadrilli, A.; Buti, S.; Formica, F.; Tiseo, M.; Ardizzoni, A.
CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients
2015-01-01 Facchinetti, Francesco; Aldigeri, Raffaella; Aloe, Rosalia; Bortesi, Beatrice; Ardizzoni, Andrea; Tiseo, Marcello
Cystic brain metastases and RET fusion in lung cancer
2020-01-01 Remon, J.; Facchinetti, F.; Besse, B.; Tiseo, M.
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC
2017-01-01 Mazzaschi, G.; Madeddu, D.; Veneziani, M.; Sogni, F.; Armani, G.; Frati, C.; Lagrasta, C.; Falco, A.; Lorusso, B.; Vilella, R.; Mangiaracina, C.; Bocchialini, G.; Silini, E. M.; Facchinetti, F.; Ardizzoni, A.; Missale, G.; Tiseo, M.; Quaini, F.
Exploring the role of respiratory microbiome in lung cancer: A systematic review
2021-01-01 Perrone, F.; Belluomini, L.; Mazzotta, M.; Bianconi, M.; Di Noia, V.; Meacci, F.; Montrone, M.; Pignataro, D.; Prelaj, A.; Rinaldi, S.; Russano, M.; Sartori, G.; Bironzo, P.; Facchinetti, F.; Menis, J.; Tiseo, M.; Galetta, D.; Novello, S.; Pilotto, S.
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis
2021-01-01 Facchinetti, F.; Maio, M. D.; Perrone, F.; Tiseo, M.
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
2020-01-01 Facchinetti, F.; Mazzaschi, G.; Barbieri, F.; Passiglia, F.; Mazzoni, F.; Berardi, R.; Proto, C.; Cecere, F. L.; Pilotto, S.; Scotti, V.; Rossi, S.; Del Conte, A.; Vita, E.; Bennati, C.; Ardizzoni, A.; Cerea, G.; Migliorino, M. R.; Sala, E.; Camerini, A.; Bearz, A.; De Carlo, E.; Zanelli, F.; Guaitoli, G.; Garassino, M. C.; Ciccone, L. P.; Sartori, G.; Toschi, L.; Dall'Olio, F. G.; Landi, L.; Pizzutilo, E. G.; Bartoli, G.; Baldessari, C.; Novello, S.; Bria, E.; Cortinovis, D. L.; Rossi, G.; Rossi, A.; Banna, G. L.; Camisa, R.; Di Maio, M.; Tiseo, M.
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
2020-01-01 Russo, G. L.; Facchinetti, F.; Tiseo, M.; Garassino, M. C.; Ferrara, R.
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis
2021-01-01 Guaitoli, G.; Tiseo, M.; Di Maio, M.; Friboulet, L.; Facchinetti, F.
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature
2018-01-01 Pellegrino, Benedetta; Facchinetti, Francesco; Bordi, Paola; Silva, Mario; Gnetti, Letizia; Tiseo, Marcello
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy
2021-01-01 Mazzaschi, G.; Leonetti, A.; Minari, R.; Gnetti, L.; Quaini, F.; Tiseo, M.; Facchinetti, F.
Moving immune checkpoint blockade in thoracic tumors beyond NSCLC
2016-01-01 Facchinetti, Francesco; Marabelle, Aurélien; Rossi, Giulio; Soria, Jean-Charles; Besse, Benjamin; Tiseo, Marcello
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
2017-01-01 Facchinetti, Francesco; Rossi, Giulio; Bria, Emilio; Soria, Jean-Charles; Besse, Benjamin; Minari, Roberta; Friboulet, Luc; Tiseo, Marcello
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?
2020-01-01 Facchinetti, F.; Leonetti, A.; Tiseo, M.
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
2021-01-01 Minari, R.; Bonatti, F.; Mazzaschi, G.; Dodi, A.; Facchinetti, F.; Gelsomino, F.; Cinquegrani, G.; Squadrilli, A.; Bordi, P.; Buti, S.; Bersanelli, M.; Leonetti, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Quaini, F.; Ardizzoni, A.; Tiseo, M.
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination
2021-01-01 Gelsomino, F.; Facchinetti, F.; Sisi, M.; Zielli, T.; Tiseo, M.; Ardizzoni, A.
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib
2019-01-01 Facchinetti, F.; Gnetti, L.; Balestra, V.; Silva, M.; Silini, E. M.; Ventura, L.; Majori, M.; Bordi, P.; Tiseo, M.
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
2019-01-01 Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Zecca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib
2020-01-01 De Giglio, A.; Lamberti, G.; Facchinetti, F.; Genova, C.; Andrini, E.; Dal Bello, M. G.; Tiseo, M.; Metro, G.; Chiari, R.; Ricciuti, B.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib | 1-gen-2021 | Gozzi, F.; Tiseo, M.; Facchinetti, F.; Gandolfi, S.; Rubino, P. | |
| CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors | 1-gen-2020 | Dall'Olio, F. G.; Abbati, F.; Facchinetti, F.; Massucci, M.; Melotti, B.; Squadrilli, A.; Buti, S.; Formica, F.; Tiseo, M.; Ardizzoni, A. | |
| CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients | 1-gen-2015 | Facchinetti, Francesco; Aldigeri, Raffaella; Aloe, Rosalia; Bortesi, Beatrice; Ardizzoni, Andrea; Tiseo, Marcello | |
| Cystic brain metastases and RET fusion in lung cancer | 1-gen-2020 | Remon, J.; Facchinetti, F.; Besse, B.; Tiseo, M. | |
| Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC | 1-gen-2017 | Mazzaschi, G.; Madeddu, D.; Veneziani, M.; Sogni, F.; Armani, G.; Frati, C.; Lagrasta, C.; Falco, A.; Lorusso, B.; Vilella, R.; Mangiaracina, C.; Bocchialini, G.; Silini, E. M.; Facchinetti, F.; Ardizzoni, A.; Missale, G.; Tiseo, M.; Quaini, F. | |
| Exploring the role of respiratory microbiome in lung cancer: A systematic review | 1-gen-2021 | Perrone, F.; Belluomini, L.; Mazzotta, M.; Bianconi, M.; Di Noia, V.; Meacci, F.; Montrone, M.; Pignataro, D.; Prelaj, A.; Rinaldi, S.; Russano, M.; Sartori, G.; Bironzo, P.; Facchinetti, F.; Menis, J.; Tiseo, M.; Galetta, D.; Novello, S.; Pilotto, S. | |
| First-line immunotherapy in non-small cell lung cancer patients with poor performance status: A systematic review and meta-analysis | 1-gen-2021 | Facchinetti, F.; Maio, M. D.; Perrone, F.; Tiseo, M. | |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status | 1-gen-2020 | Facchinetti, F.; Mazzaschi, G.; Barbieri, F.; Passiglia, F.; Mazzoni, F.; Berardi, R.; Proto, C.; Cecere, F. L.; Pilotto, S.; Scotti, V.; Rossi, S.; Del Conte, A.; Vita, E.; Bennati, C.; Ardizzoni, A.; Cerea, G.; Migliorino, M. R.; Sala, E.; Camerini, A.; Bearz, A.; De Carlo, E.; Zanelli, F.; Guaitoli, G.; Garassino, M. C.; Ciccone, L. P.; Sartori, G.; Toschi, L.; Dall'Olio, F. G.; Landi, L.; Pizzutilo, E. G.; Bartoli, G.; Baldessari, C.; Novello, S.; Bria, E.; Cortinovis, D. L.; Rossi, G.; Rossi, A.; Banna, G. L.; Camisa, R.; Di Maio, M.; Tiseo, M. | |
| Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer | 1-gen-2020 | Russo, G. L.; Facchinetti, F.; Tiseo, M.; Garassino, M. C.; Ferrara, R. | |
| Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: A systematic review and meta-analysis | 1-gen-2021 | Guaitoli, G.; Tiseo, M.; Di Maio, M.; Friboulet, L.; Facchinetti, F. | |
| Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature | 1-gen-2018 | Pellegrino, Benedetta; Facchinetti, Francesco; Bordi, Paola; Silva, Mario; Gnetti, Letizia; Tiseo, Marcello | |
| Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy | 1-gen-2021 | Mazzaschi, G.; Leonetti, A.; Minari, R.; Gnetti, L.; Quaini, F.; Tiseo, M.; Facchinetti, F. | |
| Moving immune checkpoint blockade in thoracic tumors beyond NSCLC | 1-gen-2016 | Facchinetti, Francesco; Marabelle, Aurélien; Rossi, Giulio; Soria, Jean-Charles; Besse, Benjamin; Tiseo, Marcello | |
| Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition | 1-gen-2017 | Facchinetti, Francesco; Rossi, Giulio; Bria, Emilio; Soria, Jean-Charles; Besse, Benjamin; Minari, Roberta; Friboulet, Luc; Tiseo, Marcello | |
| Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? | 1-gen-2020 | Facchinetti, F.; Leonetti, A.; Tiseo, M. | |
| PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors | 1-gen-2021 | Minari, R.; Bonatti, F.; Mazzaschi, G.; Dodi, A.; Facchinetti, F.; Gelsomino, F.; Cinquegrani, G.; Squadrilli, A.; Bordi, P.; Buti, S.; Bersanelli, M.; Leonetti, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Quaini, F.; Ardizzoni, A.; Tiseo, M. | |
| PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination | 1-gen-2021 | Gelsomino, F.; Facchinetti, F.; Sisi, M.; Zielli, T.; Tiseo, M.; Ardizzoni, A. | |
| Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib | 1-gen-2019 | Facchinetti, F.; Gnetti, L.; Balestra, V.; Silva, M.; Silini, E. M.; Ventura, L.; Majori, M.; Bordi, P.; Tiseo, M. | |
| The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC | 1-gen-2019 | Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Zecca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello | |
| Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib | 1-gen-2020 | De Giglio, A.; Lamberti, G.; Facchinetti, F.; Genova, C.; Andrini, E.; Dal Bello, M. G.; Tiseo, M.; Metro, G.; Chiari, R.; Ricciuti, B. |